Mobile Site ›
Print Page Email Page

Interpretive Handbook

‹ Back to index | Back to list | More information

Test 200269:
Direct LDL, Serum

Clinical Information Discusses physiology, pathophysiology, and general clinical aspects, as they relate to a laboratory test

Increased low-density lipoprotein cholesterol (LDLC) is widely recognized as a risk factor for atherosclerotic disease, specifically coronary atherosclerosis.

 

Diminished or absent LDLC may be a cause of polyneuropathy.

Useful For Suggests clinical disorders or settings where the test may be helpful

Evaluation of cardiovascular risks

 

Diagnosis of hypobetalipoproteinemia (values <80 mg/dL)

 

Diagnosis of abetalipoproteinemia (values undetectable)

Interpretation Provides information to assist in interpretation of the test results

Evaluation of cardiovascular risk is based on the following range of values:

Desirable: <100 mg/dL

Low risk: 100-129 mg/dL

Borderline high: 130-159 mg/dL

High: 160-189 mg/dL

Very high: > or =190 mg/dL

 

Values <80 mg/dL indicate hypobetalipoproteinemia.

 

Nondetectable low-density lipoprotein cholesterol indicates abetalipoproteinemia. Related polyneuropathy may exist in affected individuals.

Cautions Discusses conditions that may cause diagnostic confusion, including improper specimen collection and handling, inappropriate test selection, and interfering substances

No stimulants, alcohol, or other depressants for at least 24 hours before specimen collection

 

No food for 12-14 hours before collection

 

Water may be taken as needed

 

Physicians must advise diabetic patients on necessary medications and snacks

Reference Values Describes reference intervals and additional information for interpretation of test results. May include intervals based on age and sex when appropriate. Intervals are Mayo-derived, unless otherwise designated. If an interpretive report is provided, the reference value field will state this.

<160 mg/dL

Clinical References Provides recommendations for further in-depth reading of a clinical nature

Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III), JAMA 2001;285:2486-2497